Kinnari Patel - 11 Feb 2025 Form 4 Insider Report for ROCKET PHARMACEUTICALS, INC. (RCKT)

Role
President, Head of R&D and Chief Operating Officer
Signature
/s/ Martin Wilson, as attorney-in-fact for Kinnari Patel
Issuer symbol
RCKT
Transactions as of
11 Feb 2025
Net transactions value
$0
Form type
4
Filing time
13 Feb 2025, 16:01:32 UTC
Previous filing
25 Nov 2024
Next filing
25 Feb 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RCKT Common Stock Award $0 +57,786 +15% $0.000000 450,181 11 Feb 2025 Direct F1
holding RCKT Common Stock 5,675 11 Feb 2025 By Spouse
holding RCKT Common Stock 104,927 11 Feb 2025 By Adaptive Technology LLC F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RCKT Stock Option (Right to Buy) Award $0 +172,214 $0.000000 172,214 11 Feb 2025 Common Stock 172,214 $9.88 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represent RSUs that convert to common stock on a one-for-one basis. One-third (1/3) of such RSUs will become fully vested on February 11, 2026, with the remaining shares vesting in equal quarterly installments over the following two years.
F2 The shares are held indirectly through Adaptive Technology, LLC, a limited liability company that is owned and managed by the reporting person's husband.
F3 This option represents a right to purchase a total of 172,214 shares of the Issuer's Common Stock, one-third of which will become fully vested and exercisable on February 11, 2026, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.

Remarks:

President, Head of R&D and Chief Operating Officer